Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

The Highly Tumorigenic 3,4-Dihydrodiol Is a Principal Metabolite Formed from Dibenzo[a,h]anthracene by Liver Enzymes

M. NORDQVIST, D. R. THAKKER, W. LEVIN, H. YAGI, D. E. RYAN, P. E. THOMAS, A. H. CONNEY and D. M. JERINA
Molecular Pharmacology September 1979, 16 (2) 643-655;
M. NORDQVIST
Laboratory of Bioorganic Chemistry, National Institute of Arthritis, Metabolism and Digestive Diseases, National Institutes of Health, Bethesda, MD 20014
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. R. THAKKER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. LEVIN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. YAGI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. E. RYAN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. E. THOMAS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. H. CONNEY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. M. JERINA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Pretreatment of rats with 3-methylcholanthrene or Aroclor-1254 caused a 2- to 3-fold enhancement in the rate of metabolism of [14C]-dibenzo[a,h]anthracene (DBA) by liver microsomes and altered the relative amounts of some of the metabolites formed compared to metabolism by microsomes from untreated rats. These changes consisted mainly of a decrease in phenols and an increase in unidentified minor metabolites. Pretreatment of rats with phenobarbital caused less marked changes in the profile of metabolites formed from DBA, and the rate of metabolism of DBA was significantly reduced per nmol of cytochrome P-450 compared to microsomes from untreated rats. Under all incubation conditions, DBA 3,4-dihydrodiol was the major dihydrodiol metabolite which accounted for 24-28% of the total metabolites. Less than half this amount of the 1,2-dihydrodiol was formed, and only trace amounts of the K-region 5,6-dihydrodiol could be detected. Two major phenolic metabolite fractions were detected. After 3-methylcholanthrene- or Aroclor-pretreatment, metabolites more polar than the dihydrodiols were also formed. In the absence of epoxide hydrase, DBA was converted primarily into phenols by a purified and reconstituted cytochrome P-448 monooxygenase system. Addition of highly purified epoxide hydrase resulted in the formation of DBA 1,2- and 3,4-dihydrodiols as well as more polar metabolites with a concomitant decrease in the amounts of phenolic metabolites. The predominance of DBA 3,4-dihydrodiol as a metabolite on incubation of DBA either with rat liver microsomes or with the highly purified, reconstituted monooxygenase system in the presence of epoxide hydrase is of considerable importance since this is the most potent carcinogenic metabolite of DBA presently known. The 3,4-dihydrodiol formed from DBA by liver microsomes from 3-methylcholanthrene-treated rats was found to be 60% optically pure. Evidence is presented which indicates that bay region diol epoxides are formed from racemic DBA 3,4-dihydrodiol.

ACKNOWLEDGMENTS We wish to thank Mrs. Janet Deyhle and Mrs. Rosemary DePue for their help in the preparation of this manuscript. One of us (M.N.) acknowledges a Fogarty International Fellowship and a scholarship from the Fulbright Commission for International Exchange of Scholars.

  • Copyright © 1979 by Academic Press, Inc.

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology
Vol. 16, Issue 2
1 Sep 1979
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Editorial Board (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Highly Tumorigenic 3,4-Dihydrodiol Is a Principal Metabolite Formed from Dibenzo[a,h]anthracene by Liver Enzymes
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

The Highly Tumorigenic 3,4-Dihydrodiol Is a Principal Metabolite Formed from Dibenzo[a,h]anthracene by Liver Enzymes

M. NORDQVIST, D. R. THAKKER, W. LEVIN, H. YAGI, D. E. RYAN, P. E. THOMAS, A. H. CONNEY and D. M. JERINA
Molecular Pharmacology September 1, 1979, 16 (2) 643-655;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

The Highly Tumorigenic 3,4-Dihydrodiol Is a Principal Metabolite Formed from Dibenzo[a,h]anthracene by Liver Enzymes

M. NORDQVIST, D. R. THAKKER, W. LEVIN, H. YAGI, D. E. RYAN, P. E. THOMAS, A. H. CONNEY and D. M. JERINA
Molecular Pharmacology September 1, 1979, 16 (2) 643-655;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Mechanism of the selective action of paraherquamide A
  • Fatty Acid Amide Hydrolase in Cisplatin Nephrotoxicity
  • Use-Dependent Relief of A-887826 Inhibition
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics